Since its discovery in the 1990s, programmed cell death protein 1 (PD-1) has been regarded as a leading target in cancer ...

Cancer immunotherapy drugs called immune checkpoint inhibitors take the brakes off the body’s immune system, allowing it to ...

Since its discovery in the 1990s, "programmed cell death protein 1," or PD-1, has been regarded as a leading target in cancer treatments. A "checkpoint" receptor that often resides on the surface ...

Scientists have discovered significant discrepancies in PD-1 between humans and rodents, indicating that common lab models ...

A novel molecular tool developed by a Lehigh University professor of biological sciences is enabling scientists to precisely ...

Volrustomig is under clinical development by AstraZeneca and currently in Phase II for Malignant Neoplasms. According to GlobalData, Phase II drugs for Malignant Neoplasms does not have sufficient ...

Cell death terminates normal cellular functions, including respiration, metabolism, growth and proliferation. Cell death can be non-programmed ... gemcitabine and Mcl-1 inhibitor efficiently ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today annou ...

Westlake University in China and the California Institute of Technology have designed a protein-based system ... to stay alive or undergo programmed cell death. Cells naturally process multiple ...

Since its discovery in the 1990s, "programmed cell death protein 1," or PD-1, has been regarded as a leading target in cancer treatments. A "checkpoint" receptor that often resides on the surface of ...